Ajani J A, Pazdur R, Dumas P, Fairweather J
Department of Gastrointestinal Oncology and Digestive Diseases, U.T.M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Invest New Drugs. 1998;16(2):175-7. doi: 10.1023/a:1006093008179.
Taxol represents a new class of anticancer agents with activity against a wide variety of solid tumors. In preclinical systems, its cytotoxicity is schedule dependent with prolonged exposure being more effective. We studied a 120-hour infusion schedule of Taxol in patients with metastatic measurable colorectal carcinoma who had had one prior 5-FU-based chemotherapy.
Patients with measurable metastatic colorectal carcinoma were eligible. Patients had to have normal liver, renal, and bone marrow functions. Written informed consent was obtained from all patients. The starting dose of Taxol was 150 mg/m2 infused over 120-hours in the outpatient setting. Taxol was repeated every 21 days.
Fifteen patients were registered. Among 14 evaluable patients, we did not observe any complete or partial response. Major toxicity included myelosuppression and mucositis. There was no treatment-related death.
Taxol administered by this schedule was found ineffective in patients with metastatic colorectal carcinoma who had previously received one 5-FU-based chemotherapy.
紫杉醇是一类新型抗癌药物，对多种实体瘤具有活性。在临床前研究中，其细胞毒性具有时间依赖性，延长暴露时间更有效。我们研究了紫杉醇在接受过一次基于5-氟尿嘧啶化疗的可测量转移性结直肠癌患者中的120小时输注方案。
可测量转移性结直肠癌患者符合条件。患者必须具有正常的肝、肾和骨髓功能。所有患者均获得书面知情同意书。紫杉醇起始剂量为150mg/m²，在门诊环境中120小时内输注完毕。每21天重复使用紫杉醇。
登记了15例患者。在14例可评估患者中，未观察到任何完全缓解或部分缓解。主要毒性包括骨髓抑制和粘膜炎。没有与治疗相关的死亡。
对于先前接受过一次基于5-氟尿嘧啶化疗的转移性结直肠癌患者，按此方案给药的紫杉醇被发现无效。
